Impact of body mass index (BMI) on the efficacy and safety of halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion in patients with plaque psoriasis

被引：0
|
作者：
Lebwohl, Mark G. [1 ]
Del Rosso, James Q. [2 ]
Alonso-Llamazares, Javier [3 ]
Lattouf, Mark [4 ]
Jacobson, Abby [4 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Thomas Dermatol, JDR Dermatol Res, Las Vegas, NV USA
[3] Miami Vet Affairs Healthcare Syst, Miami, FL USA
[4] Ortho Dermatol, Bridgewater, NJ USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27124
引用
收藏
页码：AB130 / AB130
页数：1
相关论文
共 50 条
  • [21] Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis
    Lebwohl, Mark G.
    Sugarman, Jeffrey L.
    Gold, Linda Stein
    Pariser, David M.
    Lin, Tina
    Pillai, Radhakrishnan
    Martin, Gina
    Harris, Susan
    Israel, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (01) : 282 - 285
  • [22] THE EFFICACY OF HALOBETASOL PROPIONATE (0.01%) AND TAZAROTENE (0.045%) FIXED COMBINATION RELATIVE TO OTHER TOPICAL THERAPIES AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: A NETWORK META-ANALYSIS
    Lozano-Ortega, G.
    Rogula, B.
    Gaudet, V
    Mickle, A.
    Johnston, K.
    Barbeau, M.
    VALUE IN HEALTH, 2019, 22 : S363 - S363
  • [23] Safety and Efficacy of Halobetasol Propionate Lotion 0.01% in the Treatment of Moderate to Severe Plaque Psoriasis: A Pooled Analysis of 2 Phase 3 Studies
    Sugarman, Jeffrey L.
    Weiss, Jonathan S.
    Tanghetti, Emil A.
    Soung, Jennifer
    Yamauchi, Paul S.
    Lin, Tina
    Harris, Susan
    Martin, Gina
    Pillai, Radhakrishnan
    CUTIS, 2019, 103 (02): : 111 - +
  • [24] Long-term management of moderate to severe plaque psoriasis: Maintenance of treatment success following cessation of fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in patients with baseline body surface area of 6%-12%
    Gold, Linda Stein
    Weiss, Jonathan S.
    Green, Lawrence J.
    Kircik, Leon
    Lin, Tina
    Harris, Susan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB36 - AB36
  • [25] A CANADIAN NETWORK META-ANALYSIS OF THE EFFICACY OF HALOBETASOL PROPIONATE (0.01%) AND TAZAROTENE (0.045%) FIXED COMBINATION RELATIVE TO OTHER TOPICAL THERAPIES AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
    Lozano-Ortega, G.
    Rogula, B.
    Gaudet, V
    Mickle, A.
    Johnston, K.
    Barbeau, M.
    VALUE IN HEALTH, 2020, 23 : S362 - S362
  • [26] Fixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%-5% Affected Body Surface Area
    Tanghetti, Emil A.
    Bhatia, Neal
    Drew, Scott
    Jacobson, Abby
    JOURNAL OF DRUGS IN DERMATOLOGY, 2021, 20 (08) : 829 - 836
  • [27] THE COST-EFFECTIVENESS OF HALOBETASOL PROPIONATE (0.01%) AND TAZAROTENE (0.045%) FIXED COMBINATION RELATIVE TO OTHER TOPICAL THERAPIES IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: A CANADIAN ANALYSIS
    Lakzadeh, P.
    Lozano-Ortega, G.
    Gaudet, V
    Johnston, K.
    Barbeau, M.
    VALUE IN HEALTH, 2019, 22 : S363 - S364
  • [28] A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis
    Kerdel, Francisco A.
    Draelos, Zoe D.
    Tyring, Stephen K.
    Lin, Tina
    Pillai, Radhakrishnan
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (04) : 333 - 339
  • [29] Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials
    Lebwohl, Mark G.
    Sugarman, Jeffrey L.
    Gold, Linda Stein
    Lin, Tina
    Israel, Robert
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (10) : 1012 - 1018
  • [30] Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials
    Green, Lawrence J.
    Kerdel, Francisco A.
    Cook-Bolden, Fran E.
    Bagel, Jerry
    Lin, Tina
    Martin, Gina
    Pillai, Radhakrishnan
    Israel, Robert
    Ramakrishna, Tage
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (10) : 1062 - 1069
12345